HBOT Conversations:
Tom Fox (Part 2)
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years, and has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. Tom is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita-RTP team in 2022 as the Safety Director, and is joining us in a 2-part series to discuss the history of Hyperbaric Oxygen Therapy and dive into his personal experience healing patients with HBOT.
Watch the Podcast
In Part 2 of Ed di Girolamo’s conversation with Tom Fox, we dive further into the history of hyperbarics and how this all plays a part in where we are today in understanding, administering, and healing patients with HBOT. Part 1 discussed HBOT history up to Cunningham’s ball in the 1920s.
We start our conversation discussing the time when operating rooms were essentially hyperbaric chambers. Tom explains that was before the FDA, and they started using pressurized rooms and oxygen as an alternative method to do heart surgery and replace valves, because if you super-saturate the body during surgery you can extend the length of time that a patient can go without oxygen. The time was upwards of 13 to 15 minutes, allowing the surgeon more time to do valve replacement. This could have been a real game-changer for the HBOT industry, but it was short-lived because the bypass machine replaced hyperbaric operating rooms.
Then in 1963 the HBOT industry had a set-back. President John F. Kennedy had a premature son who had a condition that lead to a hypoxic event (lack of oxygen) following birth. The child was placed in a hyperbaric oxygen chamber at Harvard. Initially, he did very well. But, 60 years ago we didn’t know a lot about the toxic effects and the therapeutic limits of the use of oxygen. He was treated at a much greater pressure than physicians would treat people today, and this little baby was treated for extended time, up to 7 hours! So Hyperbaric Oxygen Therapy was seen in a negative light right after that, because as different physicians got involved in it, they said that it was HBOT that killed John F. Kennedy’s baby. That incident made it difficult for the hyperbaric industry to bounce back into a positive light. Yet, there was a saving grace; thankfully around this same time and soon after Europe and the USSR were developing whole systems and procedures to administer HBOT. They had hospitals in a former USSR that was using hyperbarics as their principal treatment; so when physicians here in the US wanted to treat with HBOT, they used a machine to translate a Russian manual, so they could get it right.
Moving forward, a lot of the physicians that were fostering and having great success treating with HBOT came out of the military. Tom explains that he has been in the HBOT industry for a long time, 31 years and he has been in the presence of some of the true pioneers in hyperbarics.
And then the Undersea Medical Society enters the picture…..
Tom explains, “Now in 1967, that’s kind of when the Undersea Medical Society came around, you know, what they did was they go, ‘Okay, this is the Wild West. We need to rein this in and we need to identify the rationale, why we’re doing this so that we can structure this into an offering in medicine, a therapeutic offering into medicine.’ And you had doctors like Dr. Kindwall, Dr. Hart, these are pioneers at the time that were instrumental in the formation of the new Medical Society. You know, that was both a curse and it had a lot of positive effects, too. But the thing was they put hyperbarics and undersea medicine together, and that’s been a problem. It certainly prevents the thought of clinical hyperbarics progressing independently of diving medicine.
Next, the FDA worked together with the Undersea & Hyperbaric Medical Society, and together they produced a committee report that looked at the indications. The indications were a lot more than what we have today, and since then it’s been refined.
Tom stresses that there’s an art to properly using Hyperbaric Oxygen Therapy, and he states the following —
“In the right hands, hyperbarics can do wonderful things. In the wrong hands, most often it won’t do bad things, but it will not have the desired results.”
di Girolamo and Tom Fox further dive into the art of using hyperbarics properly, and even how incorporating things like a good diet and exercise will play just as much of an important part in a person’s health. Tom stresses that HBOT is not a cure in most cases, but it can be an extremely useful tool to help someone get closer to their baseline.
The one thing that has stood the test of time is that no one can deny that HBOT is effective for hypoxia and inflammation. Any indication that has those two conditions associated with it, can be positively affected by using Hyperbaric Oxygen Therapy. He ends this segment encouraging everyone to keep an open mind about the god-given miracle of combining oxygen and pressure.
“I think you’re going to find that whether you’re dealing with something currently or you may be having, you know, something going on that you’re not even aware of, HBOT is not going to hurt you. It’s a good option.”
Guests

Thomas M. Fox, MAS,MS, CHT - Safety Director at Extivita RTP & Research Physiologist for the Hyperbaric Institute for Research and Training
Tom is the Research Physiologist for the Hyperbaric Institute for Research and Training, a division of Island Hyperbaric Centre in Pincourt QC. He has worked in the field of Clinical Hyperbaric Oxygen for the last 30 years. During this time, he has been intimately involved with the implementation and the development of the US Army’s Clinical Hyperbaric Service at Dwight David Eisenhower Army Medical Center. He has provided contract hyperbaric services since 1997. Prior to accepting his current position in Quebec, Canada, Mr. Fox served as the Chief of the Atmospherics Branch of the U.S. Army School of Aviation Medicine, Fort Rucker Alabama. In this capacity, he was responsible for hyperbaric/ hypobaric operations and training of US and NATO aviators, flight surgeons and flight medics. Mr. Fox is a senior army aviator and flew twelve years as a Medical Evacuation Pilot for the US Army.
Tom joined the Extivita team in 2022 as the Safety Director, helping Extivita to maintain a healthy and safe environment for exceptional patient care.
Subscribe Now, It’s Free!
Recent HBOT News
Combining infliximab, anti-MAP and hyperbaric oxygen therapy for resistant fistulizing Crohn’s disease.
Fistulizing Crohn’s disease (CD) presents a therapeutic challenge as fistulae are notoriously difficult to heal. Mycobacterium avium ss paratuberculosis (MAP) treatment in CD is gaining attention. We evaluated healing of CD fistula(e) using a novel combination therapy. Nine consecutive patients who failed to heal fistulae on conventional treatment including anti-TNF, were treated with at least three doses of infliximab, 18-30 courses of hyperbaric oxygen therapy and anti-MAP antibiotics comprising rifabutin, clarithromycin and clofazimine. All patients achieved complete healing of fistulae by 6-28 weeks and follow-up for mean 18 months.
Clinical Trial – Dexmedetomidine Versus Magnesium Sulphate for Caesarean Delivery
Regional anesthesia has become more popular in cesarean deliveries because most of the
parturients prefer being awake during the birth process. In addition, regional anesthesia may
be a safer method than general. In spinal anesthesia local anesthetics alone may not be
enough for an effective postoperative analgesia and hemodynamic stability of the patient wich
is crucial during cesarean section. So far many adjuvants have been used to augment the
analgesia produced by intrathecal local anesthetics and to reduce their adverse effects .
Various intrathecal adjuvants to local anaesthetics have found to improve the quality and
extend duration of spinal block. Prolongation of duration of spinal block is desirable both
for long procedures and for postoperative pain relief. Efficacy and safty of intrathecal
magnesium as analgesic adjuvant has been tested by several clinical trails in recent
years.Antinociceptive effect of magnesium appears to be relevant for the management of
chronic and post operative pain. These effects are primarily based on regulation of calcium
influx in to the cell. Magnesium blocks calcium influx and non competitively antagonizes NMDA
channels. NMDA receptor signelling plays an impartent in determining the duration of acute
pain3).) addition of magnesium to spinal anaesthesia improved postoperative analgesia in
orthopedic setting. addition of intrathecal magnesium sulfate to 10 mg bupivacaine plus 25µg
fentanyl prolonged spinal anaesthesia in patients undergoing lower extremity surgery.
Dexmedetomidine is a highly selective 2-adrenergic agonist which has been used as
pre-medication and as an adjuvant to general anesthesia.Dexmedetomidine have several
beneficial actions during perioperative period. They decrease sympathetic tone with
attenuation of the neuroendocrine and haemodynamic response to anaesthesia and surgery,
reduce anaesthetic and opiod requirement, cause sedation and analgesia. Dexmedetomidine was
first introduced into clinical practice as a short term intravenous sedative in intensive
care. Like any other adjuvant dexmedetomidine is not free from adverse effects. Use of
dexmedetomidine is often associated with a decrease in heart rate and blood
pressure.Dexmedetomidine was used to enhance the analgesic property of local anaesthetics
like lidocaine bupivacaine and ropivacaine. In vivo and in vitro studies indicated that these
local anaesthetics had significant neurotoxicity. Dexmedetomidine showed protective or growth
promoting properties in tissues, including nerve cells from cortex. Intrathecal
dexmedetomidine has a neuroprotective effect similar to methylprednisolone.
The mechanism by which intrathecal alpha 2-adrenergic agonists prolong the motor and sensory
block of local anesthetics is not clear. It may be an additive or synergistic effect
secondary to the different mechanisms of action of local anesthetic and alpha 2 adrenergic
agonist. The local anesthetics act by blocking sodium channels, whereas the alpha 2
adrenergic agonist acts by binding to pre synapyic C fibre and post synaptic dorsal horn
neurons. Intrathecal alpha 2 adrenergic agonist produce analgesia by depressing the realease
of C fibre transmission by hyperpolarization of post synaptic dorsal horn neurons. Li et al
observed that Glutamate is involved in excitatory neurotransmission nociception and plays an
essential role in relaying noxious stimuli in the spinal cord. Intrathecal injection of alpha
2 adrenergic agonists produces potent antinociceptive effects by altering spinal
neurotransmitter release and effectively treats acute pain.
Efficacy of hyperbaric oxygen therapy combined with mild hyperthermia for improving the anti-tumour effects of carboplatin.
Abstract: The aim of this study was to evaluate the effects of hyperbaric oxygen therapy (HBO) on the enhancement of hyperthermic chemosensitisation to carboplatin at mild temperatures in experimental tumours. SCCVII carcinoma in C3H/He mice was used to assess tumour...
